tetano
Editor, Senior Moderator
Infect Disord Drug Targets. 2013 May 8. [Epub ahead of print]
Emergence of Oseltamivir Resistance: Control and Management of Influenza Before, During and after The Pandemic.
Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R.
Source
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and The University of Sydney, New South Wales, Australia, robert.booy@health.nsw.gov.au.
Abstract
Neuraminidase inhibitors (NAIs), such as oseltamivir and zanamivir, are the medicines of choice against influenza A or B. Oseltamivir resistance can be conferred by a single point missense mutation from histidine to tyrosine at position 275 (H275Y). Oseltamivir resistance in seasonal influenza A strains rose markedly during the 2007-2008 season. Furthermore, oseltamivir resistant (OsR) strains of pandemic influenza A/ H1N1 2009 (influenza A(H1N1)pdm09) have been increasingly isolated, although the majority remain sensitive. These OsR strains retain virulence, replicative fitness and transmissibility from person to person, with outbreaks reported. Treatment options in those at risk of severe or complicated disease are limited to zanamivir which is only licenced in those over the age of 5 years; of further concern, strains demonstrating low level resistance to both oseltamivir and zanamivir have been reported. Strategies to reduce emergence of resistant strains, such as higher dose oseltamivir regimens, need further examination.
PMID:
23675925
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23675925
Emergence of Oseltamivir Resistance: Control and Management of Influenza Before, During and after The Pandemic.
Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R.
Source
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and The University of Sydney, New South Wales, Australia, robert.booy@health.nsw.gov.au.
Abstract
Neuraminidase inhibitors (NAIs), such as oseltamivir and zanamivir, are the medicines of choice against influenza A or B. Oseltamivir resistance can be conferred by a single point missense mutation from histidine to tyrosine at position 275 (H275Y). Oseltamivir resistance in seasonal influenza A strains rose markedly during the 2007-2008 season. Furthermore, oseltamivir resistant (OsR) strains of pandemic influenza A/ H1N1 2009 (influenza A(H1N1)pdm09) have been increasingly isolated, although the majority remain sensitive. These OsR strains retain virulence, replicative fitness and transmissibility from person to person, with outbreaks reported. Treatment options in those at risk of severe or complicated disease are limited to zanamivir which is only licenced in those over the age of 5 years; of further concern, strains demonstrating low level resistance to both oseltamivir and zanamivir have been reported. Strategies to reduce emergence of resistant strains, such as higher dose oseltamivir regimens, need further examination.
PMID:
23675925
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23675925